Myelopathy After Radiation Therapy and Chemotherapy with Capecitabine and Gemcitabine

Abstract

This article describes a woman with metastatic upper gastrointestinal cancer who developed thoracic myelopathy unexpectedly after standard dosage and fractionation radiotherapy. She also was receiving capecitabine and gemcitabine concomitantly. There are few reported cases of chemotherapy potentiation of spinal cord radiation toxicity. These agents are known radiosensitizers, making it likely that they contributed to this adverse outcome. As these agents are increasingly incorporated into clinical trials of combined therapy, caution will be necessary in both trial design and clinical management.

• Myelopathy
• Radiation
• Chemotherapy
• Capecitabine
• Gemcitabine